Viewpoint

Filter By:

Article Type
  • In this era of critical organ shortage, how should physicians and patients decide whether to accept or decline the offer of a specific deceased-donor liver? The author of this Viewpoint article considers recent data evaluating the impact of donor characteristics and severity of recipient disease on the decision-making process.

    • Sandy Feng
    Viewpoint
  • Idiopathic abdominal pain and chest pain of presumed digestive tract origin accounts for a considerable number of hospital admissions each year. The underlying causes of this pain remain unknown. In this Viewpoint the authors propose a novel mechanism for this undefined pain suggesting that ischemic events could be responsible.

    • Hans Gregersen
    • James Christensen
    Viewpoint
  • Endoscopy in pregnant patients presents unique concerns regarding its safety and benefit to the fetus. This Viewpoint presents an overview of the merits and potential dangers associated with endoscopy in pregnancy and discusses the impact of the latest guidelines for endoscopy in this setting.

    • Mitchell S Cappell
    Viewpoint
  • The ubiquity of gluten in foodstuffs, patient compliance, and variable patient susceptibility to gluten are all limiting factors of the gluten-free diet—the treatment of choice for celiac disease. New therapeutic strategies are emerging as a result of improved understanding of the molecular events underlying celiac disease; this Viewpoint considers whether a gluten-free diet is still adequate.

    • Rachele Ciccocioppo
    • Gino Roberto Corazza
    Viewpoint
  • Screening for colorectal cancer is effective in preventing a major cause of morbidity and mortality. Before implementing organized screening programs, however, policymakers must consider its value relative to other health-related and nonhealth-related needs. One way of doing so is cost-effectiveness analysis. This Viewpoint highlights some key issues surrounding such analysis and suggests areas for further research.

    • Michael Pignone
    Viewpoint
  • Bleeding associated with portal hypertension, is a major cause of morbidity and mortality in patients with cirrhosis. Surgery was originally the only treatment; however, over the past few decades, several new prophylactic and treatment options have evolved which call into question the role of the surgeon in the future management and treatment of bleeding portal hypertension.

    • J Michael Henderson
    • Yolanda Yang
    Viewpoint
  • Standard therapeutic strategies used to treat gastointestinal disorders are reliant on drugs and carry with them associated adverse side effects. Apheresis, a novel extracorporeal therapy, is reported to be a rapidly acting, effective treatment option without associated serious adverse side effects. This viewpoint discusses the application of this unique process for the treatment of gastrointestinal disorders.

    • Toshifumi Hibi
    • Atsushi Sakuraba
    Viewpoint
  • For many years functional heartburn has been linked to gastroesophageal reflux disease, despite a number of characteristics that set this disorder apart. As such little has been researched regarding the physiology and treatment of patients with functional heartburn as a distinct entity. This Viewpoint discusses the evidence for distinguishing this group of patients.

    • Ronnie Fass
    • Ram Dickman
    Viewpoint
  • Although it is well-known that Barrett's esophagus is a major risk factor for the development of esophageal adenocarcinoma, our understanding of the pathogenesis, causes of progression and optimal clinical management is limited. This viewpoint considers the problems of managing Barrett's esophagus, which include defining the condition and determining the value of surveillance and interventional strategies.

    • Raymond J Playford
    Viewpoint
  • Helminth parasites mostly have been eliminated in industrialized parts of the world, where the incidence of inflammatory bowel disease (IBD) is the highest. The authors propose that helminths protect the bowel by downregulating inflammatory responses. Evidence for the immune regulatory effect of helminths in animal models of colitis and in human IBD is discussed.

    • Robert W Summers
    • David E Elliott
    • Joel V Weinstock
    Viewpoint
  • Surgical techniques for gastroesophageal reflux disease (GERD) have improved in recent years. This viewpoint considers the evidence in favor of surgical therapy as an alternative to medical therapy for GERD. The safety and clinical efficacy of surgery has been demonstrated, particularly in patients with Barrett's esophagus and those with GERD-related respiratory symptoms.

    • Kurt E Roberts
    • Brant K Oelschlager
    Viewpoint
  • Endoscopic antireflux procedures are an alternative treatment for patients who do not desire medical therapy for gastroesophageal reflux disease. This Viewpoint assesses the success rates of endoscopic therapies and highlights the importance of selecting appropriate patients for this therapy.

    • Maximilian Bittinger
    • Helmut Messmann
    Viewpoint
  • The development of COX-2 inhibitors promised to achieve the benefits of NSAIDs without gastrointestinal complications. Although clinical outcome studies have demonstrated a reduction in ulcer complications with COX-2 inhibitors the magnitude of these benefits in terms of cost-effectiveness is unclear. The cardiovascular safety of these drugs also needs to be taken into account in cost-effectiveness comparisons.

    • David Y Graham
    • Francis KL Chan
    Viewpoint
  • Gallstone disease continues to be a significant problem. The recent identification of mouse genes may help determine susceptibility to the disease. An infectious etiology hypothesis has also been proposed to explain the development of gallstones. Could these discoveries lead to more effective strategies for the prevention and treatment of gallstones?

    • Sum Lee
    Viewpoint
  • At present, there is no standard treatment for cholangiocarcinoma, a fatal cancer of the biliary tree. New therapies for cholangiocarcinoma are difficult to evaluate because treatment endpoints are ill-defined. This viewpoint explains why the current endpoints are problematic and proposes a new quantitative system for assessing disease progression.

    • Gregory J Gores
    • Edwina S Baskin-Bey
    • Steven R Alberts
    Viewpoint